aflibercept   Click here for help

GtoPdb Ligand ID: 6786

Synonyms: AVE0005 | Eylea® | VEGF Trap | Zaltrap® | ziv-aflibercept
Approved drug
aflibercept is an approved drug (FDA (2011), EMA (2012))
Compound class: Peptide
Comment: Alfibercept is a fusion protein combining the Fc portion of human IgG with the ligand binding domains of the VEGRF1 and VEGRF2 receptors.

Biosimilars:
Patent protection for originator alfibercept was expected to expire earliest in Japan and China (2022), then in US (2023, if Regeneron's extended patent claims were accepted) and the EU (2025), and biosimilar development proceeded during the run-up to patent expiry [4]. Early examples included Momenta Pharmaceuticals/Mylan's M710MYL-1701P, Alteogen's ALT-L9 (a heat stabilised formulation with a predicted longer shelf-life than Eylea; NCT04058535), and Formycon/Santo Holdings' FYB203.

The table below lists Eylea biosimilars with regulatory approval.

NameTrade nameCompanyClinical PhaseIndications
aflibercept-jbvfYesafili®Biocon BiologicsUK MHRA & EMA (2023), FDA (2024)As per originator reference product; interchangeable
aflibercept-yszy (SB15)Opuviz®BiogenFDA (2024)As per originator reference product; interchangeable
aflibercept-mrbb (FYB203)Ahzantive®Formycon/Klinge BiopharmaFDA (2024), EMA (2025)As per originator reference product
aflibercept-abzv (SOK583A1)Enzeevu®SandozFDA (2024)As per originator reference product
aflibercept-ayyh (ABP 938) [3]Pavblu ®AmgenFDA (2024)As per originator reference product
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
VEGFA Primary target of this compound Hs Fusion protein Inhibition - - - 1-2,5
⤷ [1-2,5]